ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,970.84
-1.11%
Dow Jones
42,992.21
-0.77%
US Dollar vs MXN
20.3932
0.34%
Brent Oil
73.815
0.26%
Bitcoin
93,692.88
0.19%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. MaxCyte Inc (MXCT)

  7. MaxCyte Inc (MXCT) Noticias

MXCT

MaxCyte (MXCT)

MaxCyte Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MXCT
FechaHoraFuenteTítuloSímboloCompañía
27/12/202415:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MXCTMaxCyte Inc
26/12/202415:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MXCTMaxCyte Inc
23/12/202401:00GlobeNewswire Inc.MaxCyte Announces Retirement of Board Member Art MandellNASDAQ:MXCTMaxCyte Inc
10/12/202415:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
09/12/202401:00GlobeNewswire Inc.MaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceNASDAQ:MXCTMaxCyte Inc
13/11/202418:14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MXCTMaxCyte Inc
13/11/202407:05GlobeNewswire Inc.MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsNASDAQ:MXCTMaxCyte Inc
06/11/202415:55Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MXCTMaxCyte Inc
06/11/202415:05GlobeNewswire Inc.MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
31/10/202407:05GlobeNewswire Inc.MaxCyte to Participate in Two Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
16/10/202416:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MXCTMaxCyte Inc
15/10/202407:05GlobeNewswire Inc.MaxCyte Appoints Cynthia Collins to its Board of DirectorsNASDAQ:MXCTMaxCyte Inc
11/10/202407:05GlobeNewswire Inc.MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024NASDAQ:MXCTMaxCyte Inc
10/10/202407:05GlobeNewswire Inc.MaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerNASDAQ:MXCTMaxCyte Inc
16/09/202401:00GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic DiseasesNASDAQ:MXCTMaxCyte Inc
05/09/202415:05GlobeNewswire Inc.MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing ConferenceNASDAQ:MXCTMaxCyte Inc
06/08/202415:05GlobeNewswire Inc.MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
09/07/202415:05GlobeNewswire Inc.MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:MXCTMaxCyte Inc
29/05/202407:05GlobeNewswire Inc.MaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceNASDAQ:MXCTMaxCyte Inc
22/05/202407:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentNASDAQ:MXCTMaxCyte Inc
07/05/202415:05GlobeNewswire Inc.MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
10/04/202407:05GlobeNewswire Inc.MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:MXCTMaxCyte Inc
02/04/202407:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)NASDAQ:MXCTMaxCyte Inc
12/03/202415:05GlobeNewswire Inc.MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceNASDAQ:MXCTMaxCyte Inc
04/03/202415:05GlobeNewswire Inc.MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsNASDAQ:MXCTMaxCyte Inc
14/02/202415:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MXCTMaxCyte Inc
14/02/202411:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MXCTMaxCyte Inc
09/02/202407:05GlobeNewswire Inc.MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesNASDAQ:MXCTMaxCyte Inc
30/01/202407:05GlobeNewswire Inc.MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersNASDAQ:MXCTMaxCyte Inc
23/01/202407:05GlobeNewswire Inc.MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsNASDAQ:MXCTMaxCyte Inc
 Showing the most relevant articles for your search:NASDAQ:MXCT

Su Consulta Reciente

NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
NYSE
BAC
Bank of America
CCOM
US30
US 30
CCOM
SILVER
SILVER
NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
USOTC
BASFY
BASF (QX)
FX
EURMXN
Euro vs MXN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados